ROCK & ASSOCIATES for PRECISION PHARMACY
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Pharmacy PHA
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Health Issues HCR
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.